Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo D Garcia

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|June 18, 2003
beta-Catenin regulates vascular endothelial growth factor expression in colon cancerVijay Easwaran, Sang H Lee, Landon Inge, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase InhibitorsMatthew T Burger, Wooseok Han, Jiong Lan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2014
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancersPablo D Garcia, John L Langowski, Yingyun Wang, et al.
Journal of Medicinal Chemistry|October 28, 2015
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological MalignanciesMatthew T Burger, Gisele Nishiguchi, Wooseok Han, et al.
Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|June 18, 2003
beta-Catenin regulates vascular endothelial growth factor expression in colon cancerVijay Easwaran, Sang H Lee, Landon Inge, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase InhibitorsMatthew T Burger, Wooseok Han, Jiong Lan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2014
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancersPablo D Garcia, John L Langowski, Yingyun Wang, et al.
Journal of Medicinal Chemistry|October 28, 2015
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological MalignanciesMatthew T Burger, Gisele Nishiguchi, Wooseok Han, et al.
Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 2